() promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Oncoimmunology
View this publicationOncoimmunology
View this publicationBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
View this publicationClinical epigenetics
View this publicationBiomarker research
View this publicationEuropean journal of cancer (Oxford, England : 1990)
View this publicationMelanoma research
View this publicationCurrent oncology (Toronto, Ont.)
View this publicationCancer research
View this publicationJournal of fungi (Basel, Switzerland)
View this publicationJournal of immunotherapy (Hagerstown, Md. : 1997)
View this publication